Bristol Myers Squibb (CELG-RI) Amortizatization of Intangibles (2009 - 2012)
Bristol Myers Squibb (CELG-RI) posted quarterly Amortizatization of Intangibles of $102.0 million for Q2 2012, up 7.37% YoY from $95.0 million in Q3 2011, and up 0.99% sequentially from $101.0 million in Q1 2012.
Bristol Myers Squibb (CELG-RI) Amortizatization of Intangibles (2009 - 2012) Analysis & Trends
Bristol Myers Squibb has disclosed Amortizatization of Intangibles across 4 years of filings, most recently posting $102.0 million for Q2 2012.
- In Q2 2012, Amortizatization of Intangibles rose 7.37% year-over-year to $102.0 million; the TTM figure through Jun 2012 stood at $388.0 million (up 26.38% YoY), while the FY2011 annual figure was $353.0 million, up 30.26% from the prior year.
- Amortizatization of Intangibles rose to $102.0 million in Q2 2012, from $101.0 million in the prior quarter.
- Over the last five years, Amortizatization of Intangibles for CELG-RI reached as high as $102.0 million in Q2 2012 and fell as low as $59.0 million in Q3 2009.
- The 4-year median for Amortizatization of Intangibles is $75.5 million (2009), against an average of $80.3 million.
- Annual changes were most pronounced in 2010 — Amortizatization of Intangibles dropped 6.41% — and 2011, when it jumped 41.79%.
- A 4-year view of Amortizatization of Intangibles shows it stood at $78.0 million in 2009, then retreated by 6.41% to $73.0 million in 2010, then grew by 26.03% to $92.0 million in 2011, then rose by 10.87% to $102.0 million in 2012.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $102.0 million, $101.0 million, and $92.0 million for Q2 2012, Q1 2012, and Q4 2011 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amort. of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 1.70 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 931.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 596.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Bristol Myers Squibb | 244.56 Mn | -10.21 Bn | 8.07 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2012 | 102.00 Mn |
| Jun 30, 2012 | 102.00 Mn |
| Mar 31, 2012 | 101.00 Mn |
| Mar 31, 2012 | 101.00 Mn |
| Dec 31, 2011 | 92.00 Mn |
| Dec 31, 2011 | 92.00 Mn |
| Sep 30, 2011 | 93.00 Mn |
| Sep 30, 2011 | 93.00 Mn |
| Jun 30, 2011 | 95.00 Mn |
| Jun 30, 2011 | 95.00 Mn |
| Mar 31, 2011 | 73.00 Mn |
| Mar 31, 2011 | 73.00 Mn |
| Dec 31, 2010 | 73.00 Mn |
| Dec 31, 2010 | 73.00 Mn |
| Sep 30, 2010 | 66.00 Mn |
| Sep 30, 2010 | 66.00 Mn |
| Jun 30, 2010 | 67.00 Mn |
| Jun 30, 2010 | 67.00 Mn |
| Mar 31, 2010 | 65.00 Mn |
| Mar 31, 2010 | 65.00 Mn |